Antibody-mediated allograft rejection: Morphologic spectrum and serologic correlations in surveillance and for cause biopsies

Transplantation

Volumn 95, Issue 1, 2013, Pages 128-136

  Papadimitriou, John C ^a   Drachenberg, Cinthia B ^a   Ramos, Emilio ^a   Kukuruga, Debra ^a   Klassen, David K ^a   Ugarte, Richard ^a   Nogueira, Joseph ^a   Cangro, Charles ^a   Weir, Matthew R ^a   Haririan, Abdolreza ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Banff grading schema; C4d; Capillaritis; CD68; Donor specific antibody; Endothelial injury; Glomerular macrophages; Glomerulitis; HLA class I; HLA class II; Mean fluorescence index; Microvascular inflammation; Transplant glomerulopathy

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; COMPLEMENT COMPONENT C4D; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY MEDIATED ALLOGRAFT REJECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RENAL GRAFT DYSFUNCTION; RENOVASCULAR DISEASE; ULTRASTRUCTURE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTERIES; BIOPSY; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SCLEROSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872064806     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182777f28     Document Type: Article

References (45)

1. Henderson LK, Nankivell BJ, Chapman JR. Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice [review]. Am J Transplant 2011; 11: 1570.
2. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies [research support, non-U. S. government]. Am J Transplant 2005; 5: 2464.
3. Mengel M, Chapman JR, Cosio FG, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis [congresses]. Am J Transplant 2007; 7: 512.
4. Moreso F, Alperovich G, Fulladosa X, et al. Histologic findings in protocol biopsies performed in stable renal allografts under different immunosuppressive schedules [clinical trial controlled clinical trial research support, non-U. S. government]. Transplant Proc 2003; 35: 1666.
5. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study [multicenter study randomized controlled trial research support, non-U. S. government]. Am J Transplant 2007; 7: 2538.
6. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study [clinical trial randomized controlled trial]. J Am Soc Nephrol 1998; 9: 2129.
7. Yango A, Gohh R, Wang LJ, et al. The utility of 6-month protocol renal biopsy under modern immunosuppression [comparative study]. Clin Nephrol 2008; 70: 490.
8. Wilkinson A. Protocol transplant biopsies: are they really needed? [review]Clin J Am Soc Nephrol 2006; 1: 130.
9. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
10. Schwarz A, Gwinner W, Hiss M, et al. Safety and adequacy of renal transplant protocol biopsies [comparative study]. Am J Transplant 2005; 5: 1992.
11. Buchmann TN, Wolff T, Bachmann A, et al. Repeat true surveillance biopsies in kidney transplantation [comparative study]. Transplantation 2012; 93: 908.
12. Naesens M, Salvatierra O, Benfield M, et al. Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant 2012; 12: 2730.
13. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
14. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection [research support, non-U. S. government]. Transplantation 2012; 93: 41.
15. Moreso F, Lopez M, Vallejos A, et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts [research support, non-U. S. government]. Am J Transplant 2001; 1: 82.
16. Moreso F, Seron D, O'Valle F, et al. Immunephenotype of glomerular and interstitial infiltrating cells in protocol renal allograft biopsies and histological diagnosis [clinical trial research support, non-U. S. government]. Am J Transplant 2007; 7: 2739.
17. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies [research support, non-U. S. government review]. Am J Transplant 2006; 6: 2006.
18. Seron D, O'Valle F, Moreso F, et al. Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients [research support, non-U. S. government]. Transplantation 2007; 83: 649.
19. Thierry A, Thervet E, Vuiblet V, et al. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation [randomized controlled trial research support, non-U. S. government]. Am J Transplant 2011; 11: 2153.
20. Kurtkoti J, Sakhuja V, Sud K, et al. The utility of 1-and 3-month protocol biopsies on renal allograft function: a randomized controlled study [randomized controlled trial]. Am J Transplant 2008; 8: 317.
21. Gloor J, Cosio F, Lager DJ, et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment [review]. Am J Transplant 2008; 8: 1367.
22. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
23. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations [research support, N. I. H., extramural]. Am J Transplant 2009; 9: 1826.
24. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
25. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
26. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
27. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant [research support, non-U. S. government]. Am J Transplant 2012; 12: 1157.
28. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348.
29. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure [research support, non-U. S. government]. Am J Transplant 2009; 9: 2520.
30. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
31. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels [research support, non-U. S. government]. Transplantation 2008; 86: 681.
32. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90: 1478.
33. Kokko KE, Colvin RB. Below the waterlineVthe danger of de novo donor-specific HLA antibodies [comment editorial]. Am J Transplant 2012; 12: 1077.
34. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups [clinical conference research support, non-U. S. government]. Am J Transplant 2010; 10: 464.
35. Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival [review]. Clin Nephrol 2011; 75: 271.
36. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371.
37. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause [research support, non-U. S. government]. Am J Transplant 2007; 7: 1743.
38. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection [research support, non-U. S. government review]. Curr Opin Organ Transplant 2010; 15: 42.
39. Takeda A, Horike K, Ohtsuka Y, et al. Current problems of chronic active antibody-mediated rejection [review]. Clin Transplant 2011; 25: 2.
40. Bravou V, Galliford J, McLean A, et al. A case of chronic antibodymediated rejection in the making. Clin Nephrol 2012; [published online ahead of print May 14, 2012].
41. Loupy A, Hill GS, Nochy D, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure [comment letter]. Am J Transplant 2010; 10: 952; author reply 3.
42. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168.
43. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment [review]. Curr Opin Organ Transplant 2010; 15: 8.
44. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies [research support, N. I. H., extra mural research support, non-U. S. government]. Am J Transplant 2007; 7: 2757.
45. Ivanyi B. Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection [comparative study research support, non-U. S. government review]. Nephrol Dial Transplant 2003; 18: 655.